MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/ctm2.1723

Медицинская библиотека · Clinical and translational medicine · 2024

Integrative genomic analyses of European intrahepatic cholangiocarcinoma: Novel ROS1 fusion gene and PBX1 as prognostic marker.

Plum Patrick S, Hess Timo, Bertrand Denis, Morgenstern Isabelle, Velazquez Camacho Oscar, Jonas Christoph, Alidousty Christina, Wagner Britta, Roessler Stephanie, Albrecht Thomas, Becker Jessica, Richartz Vanessa, Holz Barbara, Hoppe Sascha, Poh Huay Mei, Chia Burton Kuan Hui, Chan Cheryl Xueli, Pathiraja Thushangi, Teo Audrey Sm, Marquardt Jens U, Khng Alexis, Heise Michael, Fei Yao, Thieme René, Klein Sebastian, Hong Jing Han, Dima Simona O, Popescu Irinel, Hoppe-Lotichius Maria, Buettner Reinhard, Lautem Anja, Otto Gerd, Quaas Alexander, Nagarajan Niranjan, Rozen Steve, Teh Bin Tean, Goeppert Benjamin, Drebber Uta, Lang Hauke, Tan Patrick, Gockel Ines, Schumacher Johannes, Hillmer Axel M

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Cholangiocarcinoma (CCA) is a fatal cancer of the bile duct with a poor prognosis owing to limited therapeutic options. The incidence of intrahepatic CCA (iCCA) is increasing worldwide, and its molecular basis is emerging. Environmental factors may contribute to regional differences in the mutation spectrum of European patients with iCCA, which are underrepresented in systematic genomic and transcriptomic studies of the disease.

METHODS

We describe an integrated whole-exome sequencing and transcriptomic study of 37 iCCAs patients in Germany.

RESULTS

We observed as most frequently mutated genes ARID1A (14%), IDH1, BAP1, TP53, KRAS, and ATM in 8% of patients. We identified FGFR2::BICC1 fusions in two tumours, and FGFR2::KCTD1 and TMEM106B::ROS1 as novel fusions with potential therapeutic implications in iCCA and confirmed oncogenic properties of TMEM106B::ROS1 in vitro. Using a data integration framework, we identified PBX1 as a novel central regulatory gene in iCCA. We performed extended screening by targeted sequencing of an additional 40 CCAs. In the joint analysis, IDH1 (13%), BAP1 (10%), TP53 (9%), KRAS (7%), ARID1A (7%), NF1 (5%), and ATM (5%) were the most frequently mutated genes, and we found PBX1 to show copy gain in 20% of the tumours. According to other studies, amplifications of PBX1 tend to occur in European iCCAs in contrast to liver fluke-associated Asian iCCAs.

CONCLUSIONS

By analyzing an additional European cohort of iCCA patients, we found that PBX1 protein expression was a marker of poor prognosis. Overall, our findings provide insight into key molecular alterations in iCCA, reveal new targetable fusion genes, and suggest that PBX1 is a novel modulator of this disease.

Для цитирования: Plum Patrick S, Hess Timo, Bertrand Denis, Morgenstern Isabelle, Velazquez Camacho Oscar, Jonas Christoph, Alidousty Christina, Wagner Britta, Roessler Stephanie, Albrecht Thomas, Becker Jessica, Richartz Vanessa, Holz Barbara, Hoppe Sascha, Poh Huay Mei, Chia Burton Kuan Hui, Chan Cheryl Xueli, Pathiraja Thushangi, Teo Audrey Sm, Marquardt Jens U, Khng Alexis, Heise Michael, Fei Yao, Thieme René, Klein Sebastian, Hong Jing Han, Dima Simona O, Popescu Irinel, Hoppe-Lotichius Maria, Buettner Reinhard, Lautem Anja, Otto Gerd, Quaas Alexander, Nagarajan Niranjan, Rozen Steve, Teh Bin Tean, Goeppert Benjamin, Drebber Uta, Lang Hauke, Tan Patrick, Gockel Ines, Schumacher Johannes, Hillmer Axel M. Integrative genomic analyses of European intrahepatic cholangiocarcinoma: Novel ROS1 fusion gene and PBX1 as prognostic marker.. Clinical and translational medicine. 2024. DOI: 10.1002/ctm2.1723.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.